CRISPR Therapeutics AG

NASDAQ Global Market
Back to all articles
Neutral +10

CRISPR Therapeutics (NASDAQ:CRSP) Stock Rating Lowered by Wall Street ...

📉 Wall Street Zen downgraded CRISPR Therapeutics from 'hold' to 'sell', creating a divergence in analyst sentiment.

📈 Piper Sandler raised its price target to $110.00 and Truist Financial upgraded the stock to 'strong-buy'.

💰 The company reported Q1 earnings of $1.28 per share on revenue of $1.46 million.

📉 Analysts forecast a loss of $4.89 per share for the current fiscal year.

🏢 Institutional ownership stands at 69.20% with major funds like ARK Investment Management and GSK increasing stakes.

👤 Insider Naimish Patel sold 3,786 shares worth $210,577 to cover tax withholding obligations.

Bullish Signals
  • Major institutional investors including GSK plc, Orbis Allan Gray Ltd, State Street Corp, ARK Investment Management LLC, and Norges Bank have recently added new positions or increased holdings in the stock.
  • Piper Sandler restated an 'overweight' rating with a price target of $110.00, while Truist Financial upgraded the stock to a 'strong-buy' rating.
  • The company maintains a consensus 'Moderate Buy' rating from MarketBeat with an average analyst price target of $67.78.
Risk Factors
  • Wall Street Zen downgraded the stock from a 'hold' to a 'sell' rating, indicating bearish sentiment from at least one major analyst.
  • The company reported negative net margins of -13,856.54% and a negative return on equity of -25.66% for the quarter.
  • Analysts forecast a loss of $4.89 per share for the current year, suggesting continued financial losses in the near term.
Full Analysis
CRISPR Therapeutics (NASDAQ:CRSP) received a mixed analyst outlook following a downgrade by Wall Street Zen to a 'sell' rating, which contrasts with recent upgrades from Piper Sandler and Truist Financial. The company maintains a consensus 'Moderate Buy' rating with an average price target of $67.78, though individual targets vary significantly among major institutions like Morgan Stanley and Citigroup. Financially, the biopharmaceutical firm reported Q1 earnings of $1.28 per share on revenue of $1.46 million. The company continues to operate with negative net margins and a negative return on equity, while analysts forecast a loss of $4.89 per share for the current year. Institutional ownership remains robust at 69.20%, with significant additions from GSK plc, Orbis Allan Gray Ltd, State Street Corp, ARK Investment Management LLC, and Norges Bank in recent quarters. However, insider Naimish Patel sold approximately $210,577 worth of shares to cover tax withholding obligations related to equity vesting.